Clinical research study to evaluate the effectiveness and safety of a potential oral medication for subjects with metastatic castration resistant prostate cancer


Last updated date
Study Location
City Clinic Sp. z o.o.
Warsaw, , 02-473, Poland

Study Website

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Who can take part in the study?

You may be able to join the TALAPRO-2 study if you meet the following criteria:

  • you have a diagnosis of metastatic castration-resistant prostate cancer
  • you are 18 years of age or older
  • you are willing to provide saliva, blood and tumor tissue samples for genetic testing
  • you are otherwise in reasonably good health

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

You will not be able to take part in the study if you have received:

  • systemic cancer treatment (treatment that enters the bloodstream to reach cells all over the body), not including androgen deprivation therapy and first-generation anti-androgens, since your metastatic castration-resistant prostate cancer diagnosis
  • treatment with enzalutamide, apalutamide or darolutamide (and certain other therapies used in the treatment of prostate cancer that your doctor will be able to check for you)
  • treatment with platinum-based chemotherapy within 6 months (from the last dose)

There are other requirements for participation in the study.  The study doctor will be able to explain these to you.


For Patients: Please visit the study website for more information

All other inquiries: Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

mCRPCClinical research study to evaluate the effectiveness and safety of a potential oral medication for subjects with metastatic castration resistant prostate cancer
  1. Warsaw,
  2. Chandler, Arizona
  3. Gilbert, Arizona
  4. Gilbert, Arizona
  5. Gilbert, Arizona
  6. Mesa, Arizona
  7. Mesa, Arizona
  8. Scottsdale, Arizona
  9. Tucson, Arizona
  10. Tucson, Arizona
  11. Beverly Hills, California
  12. Chula Vista, California
  13. Chula Vista, California
  14. Glendale, California
  15. Greenbrae, California
  16. La Mesa, California
  17. Loma Linda, California
  18. Loma Linda, California
  19. Long Beach, California
  20. Los Angeles, California
  21. Orange, California
  22. Palo Alto, California
  23. Rancho Mirage, California
  24. Rancho Mirage, California
  25. San Diego, California
  26. San Diego, California
  27. San Diego, California
  28. Aurora, Colorado
  29. Aurora, Colorado
  30. Aurora, Colorado
  31. Aurora, Colorado
  32. Aurora, Colorado
  33. Denver, Colorado
  34. Danbury, Connecticut
  35. New Milford, Connecticut
  36. Norwalk, Connecticut
  37. Altamonte Springs, Florida
  38. Bonita Springs, Florida
  39. Bradenton, Florida
  40. Brandon, Florida
  41. Cape Coral, Florida
  42. Celebration, Florida
  43. Clearwater, Florida
  44. Daytona Beach, Florida
  45. Fort Myers, Florida
  46. Fort Myers, Florida
  47. Fort Myers, Florida
  48. Fort Myers, Florida
  49. Gainesville, Florida
  50. Kissimmee, Florida
  51. Lakeland, Florida
  52. Largo, Florida
  53. Lecanto, Florida
  54. Naples, Florida
  55. New Port Richey, Florida
  56. Ocala, Florida
  57. Orange City, Florida
  58. Orlando, Florida
  59. Orlando, Florida
  60. Orlando, Florida
  61. Port Charlotte, Florida
  62. Saint Petersburg, Florida
  63. Sarasota, Florida
  64. Sarasota, Florida
  65. Spring Hill, Florida
  66. Tampa, Florida
  67. Tavares, Florida
  68. The Villages, Florida
  69. Venice, Florida
  70. Venice, Florida
  71. Vero Beach, Florida
  72. Wellington, Florida
  73. West Palm Beach, Florida
  74. Winter Park, Florida
  75. Athens, Georgia
  76. Atlanta, Georgia
  77. Atlanta, Georgia
  78. Atlanta, Georgia
  79. Atlanta, Georgia
  80. Fayetteville, Georgia
  81. Newnan, Georgia
  82. Newnan, Georgia
  83. Chicago, Illinois
  84. Chicago, Illinois
  85. Chicago, Illinois
  86. Chicago, Illinois
  87. Hinsdale, Illinois
  88. Hinsdale, Illinois
  89. Zion, Illinois
  90. Jeffersonville, Indiana
  91. Iowa City, Iowa
  92. Fairway, Kansas
  93. Westwood, Kansas
  94. Louisville, Kentucky
  95. New Orleans, Louisiana
  96. Baltimore, Maryland
  97. Saint Louis, Missouri
  98. Billings, Montana
  99. Billings, Montana
  100. Omaha, Nebraska
  101. Omaha, Nebraska
  102. Omaha, Nebraska
  103. Omaha, Nebraska
  104. Belleville, New Jersey
  105. Voorhees, New Jersey
  106. Albuquerque, New Mexico
  107. Farmington, New Mexico
  108. Bronx, New York
  109. Poughkeepsie, New York
  110. Syracuse, New York
  111. Cincinnati, Ohio
  112. Middleburg Heights, Ohio
  113. Oklahoma City, Oklahoma
  114. Clackamas, Oregon
  115. Clackamas, Oregon
  116. Hillsboro, Oregon
  117. Newberg, Oregon
  118. Portland, Oregon
  119. Portland, Oregon
  120. Portland, Oregon
  121. Springfield, Oregon
  122. Altoona, Pennsylvania
  123. Bethel Park, Pennsylvania
  124. Greensburg, Pennsylvania
  125. Lancaster, Pennsylvania
  126. Monroeville, Pennsylvania
  127. Philadelphia, Pennsylvania
  128. Pittsburgh, Pennsylvania
  129. Pittsburgh, Pennsylvania
  130. Pittsburgh, Pennsylvania
  131. Seneca, Pennsylvania
  132. Uniontown, Pennsylvania
  133. Washington, Pennsylvania
  134. Myrtle Beach, South Carolina
  135. Chattanooga, Tennessee
  136. Chattanooga, Tennessee
  137. Cleveland, Tennessee
  138. Harrogate, Tennessee
  139. Jefferson City, Tennessee
  140. Knoxville, Tennessee
  141. Knoxville, Tennessee
  142. Morristown, Tennessee
  143. Nashville, Tennessee
  144. Nashville, Tennessee
  145. Nashville, Tennessee
  146. El Paso, Texas
  147. Houston, Texas
  148. Round Rock, Texas
  149. Temple, Texas
  150. Farmington, Utah
  151. Salt Lake City, Utah
  152. Salt Lake City, Utah
  153. Salt Lake City, Utah
  154. South Jordan, Utah
  155. Fairfax, Virginia
  156. Fairfax, Virginia
  157. Seattle, Washington
  158. Seattle, Washington
  159. Madison, Wisconsin
  160. Madison, Wisconsin
  161. Pergamino, Buenos Aires
  162. Rosario, Santa FE
  163. Caba,
  164. Caba,
  165. Cordoba,
  166. Cordoba,
  167. Camperdown, New South Wales
  168. Darlinghurst, New South Wales
  169. Port Macquarie, New South Wales
  170. Auchenflower, Queensland
  171. Auchenflower, Queensland
  172. Brisbane, Queensland
  173. Chermside, Queensland
  174. South Brisbane, Queensland
  175. South Brisbane, Queensland
  176. Southport, Queensland
  177. Melbourne, Victoria
  178. North Melbourne, Victoria
  179. Brasschaat,
  180. Gent,
  181. Gent,
  182. Kortrijk,
  183. Ottignies,
  184. Yvoir,
  185. Rio de Janeiro, RJ
  186. Rio de Janeiro, RJ
  187. Rio de Janeiro, RJ
  188. Ijui, RS
  189. Lajeado, RS
  190. Porto Alegre, RS
  191. Porto Alegre, RS
  192. Porto Alegre, RS
  193. Barretos, SP
  194. Santo Andre, SP
  195. Santo Andre, SP
  196. Sao Paulo, SP
  197. Sao Paulo, SP
  198. Sao Paulo, SP
  199. Sao Paulo, SP
  200. São Paulo, SP
  201. Calgary, Alberta
  202. Ottawa, Ontario
  203. Chicoutimi, Quebec
  204. Montreal, Quebec
  205. Montreal, Quebec
  206. Sherbrooke, Quebec
  207. Santiago, Metropolitana
  208. Temuco, Region DE LA Araucania
  209. Temuco, Region DE LA Araucania
  210. Temuco, Region DE LA Araucania
  211. Vina del Mar, Valparaiso
  212. Vina del Mar, Valparaiso
  213. Hefei, Anhui
  214. Beiijng, Beijing
  215. Beijing, Beijing
  216. Beijing, Beijing
  217. Fuzhou, Fujian
  218. Xiamen, Fujian
  219. Wuhan, Hubei
  220. Wuhan, Hubei
  221. Nanjing, Jiangsu
  222. Suzhou, Jiangsu
  223. Wuxi, Jiangsu
  224. Nanchang, Jiangxi
  225. Shanghai, Shanghai
  226. Shanghai, Shanghai
  227. Shanghai, Shanghai
  228. Xi'an, Shanxi
  229. Chengdu, Sichuan
  230. Kunming, Yunnan
  231. Hangzhou, Zhejiang
  232. Hangzhou, Zhejiang
  233. Ningbo, Zhejiang
  234. Chongqing,
  235. Shanghai,
  236. Shanghai,
  237. Shanghai,
  238. Tianjin,
  239. Hradec Kralove,
  240. Ostrava-Poruba,
  241. Pardubice,
  242. Pardubice,
  243. Praha 10,
  244. Usti nad Labem,
  245. Helsinki,
  246. Helsinki,
  247. Helsinki,
  248. Kempele,
  249. Kuopio,
  250. Kuopio,
  251. Oulu,
  252. Tampere,
  253. Turku,
  254. Bayonne,
  255. Bayonne,
  256. Bordeaux Cedex,
  257. Bordeaux,
  258. LA ROCHE SUR YON cedex 9,
  259. Le Mans,
  260. Le Mans,
  261. Lyon CEDEX 08,
  262. Montpellier cedex 5,
  263. Paris Cedex 15,
  264. Paris,
  265. Paris,
  266. Strasbourg,
  267. Strasbourg,
  268. Suresnes Cedex,
  269. Suresnes,
  270. VILLEJUIF cedex,
  271. Erlangen, Bayern
  272. Duesseldorf,
  273. Erlangen,
  274. Hamburg,
  275. Heidelberg,
  276. Kirchheim,
  277. Muenster,
  278. Nuertingen,
  279. Ravensburg,
  280. Reutlingen,
  281. Weiden,
  282. Budapest,
  283. Budapest,
  284. Budapest,
  285. Budapest,
  286. Debrecen,
  287. Debrecen,
  288. Pecs,
  289. Haifa,
  290. Jerusalem,
  291. Petah Tikva,
  292. Tel Aviv,
  293. Bologna, BO
  294. Cremona, CR
  295. Meldola, FC
  296. Terni, TN
  297. Trento, TN
  298. Orbassano, TO
  299. Brescia,
  300. Napoli,
  301. Napoli,
  302. Nagoya, Aichi
  303. Hirosaki, Aomori
  304. Kashiwa, Chiba
  305. Matsuyama, Ehime
  306. Kure, Hiroshima
  307. Sapporo, Hokkaido
  308. Sapporo, Hokkaido
  309. Kanazawa, Ishikawa
  310. Yokohama, Kanagawa
  311. Yokosuka, Kanagawa
  312. Osaka-shi, Osaka
  313. Osakasayama, Osaka
  314. Suita, Osaka
  315. Hamamatsu, Shizuoka
  316. Meguro-ku, Tokyo
  317. Shinjuku-ku, Tokyo
  318. Chiba,
  319. Fukuoka,
  320. Kagoshima,
  321. Kumamoto,
  322. Tokushima,
  323. Yamagata,
  324. Yamagata,
  325. Goyang-si, Gyeonggi-do
  326. Goyang-si, Gyeonggi-do
  327. Busan,
  328. Daegu,
  329. Seoul,
  330. Seoul,
  331. Seoul,
  332. Seoul,
  333. Seoul,
  334. Seoul,
  335. Seoul,
  336. Seoul,
  337. Seoul,
  338. Tauranga, BAY OF Plenty
  339. Christchurch, Canterbury
  340. Hamilton, Waikato
  341. Auckland,
  342. Auckland,
  343. Gralum,
  344. Gralum,
  345. Lorenskog,
  346. Oslo,
  347. Oslo,
  348. Trondheim,
  349. Trondheim,
  350. Arequipa,
  351. Lima,
  352. Lima,
  353. Lima,
  354. Lima,
  355. Brzozow,
  356. Gdynia,
  357. Konin,
  358. Otwock,
  359. Warszawa,
  360. Braga,
  361. Coimbra,
  362. Lisboa,
  363. Lisboa,
  364. Porto,
  365. Porto,
  366. Port Elizabeth, Eastern CAPE
  367. Johannesburg, Gauteng
  368. Johannesburg, Gauteng
  369. Johannesburg, Gauteng
  370. Cape Town, Western CAPE
  371. George, Western CAPE
  372. Kraaifontein, Cape Town, Western CAPE
  373. Santiago de Compostela, A Coruna
  374. Elche, Alicante
  375. L'Hospitalet de Llobregat, Barcelona
  376. L'Hospitalet de Llobregat, Barcelona
  377. Sabadell, Barcelona
  378. El Palmar, Murcia
  379. Barcelona,
  380. Barcelona,
  381. Madrid,
  382. Madrid,
  383. Madrid,
  384. Madrid,
  385. Goteborg,
  386. Stockholm,
  387. Umeå,
  388. Umeå,
  389. Plymouth, Devon
  390. Bebington, Wirral
  391. Cornwall,
  392. Glasgow,
  393. Liverpool,
  394. London,
  395. London,
  396. London,
  397. Oxford,
18 Years+
Advanced Information
Descriptive Information
Brief Title  ICMJE Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Brief Summary This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Detailed Description Part 1 is an open-label, non-randomized, safety and PK run-in study designed to confirm the starting dose of talazoparib in combination with enzalutamide through assessment of target safety events and PK at select sites. Part 2 is a randomized, double-blind, placebo-controlled, multinational study comparing talazoparib plus enzalutamide vs. placebo plus enzalutamide in patients with mCRPC.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
To assess radiographic PFS in men with mCRPC (with no systemic treatments initiated after documentation of mCRCP) treated with talazoparib and enzalutamide vs. placebo plus enzalutamide
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Primary Purpose: Treatment
Condition  ICMJE mCRPC
Intervention  ICMJE
  • Drug: Talazoparib with enzalutamide
    Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
  • Drug: Placebo with enzalutamide
    Placebo plus enzalutamide 160 mg/day
Study Arms  ICMJE
  • Experimental: Combination arm
    Talazoparib plus enzalutamide
    Intervention: Drug: Talazoparib with enzalutamide
  • Active Comparator: Monotherapy arm
    Ezalutamide plus placebo
    Intervention: Drug: Placebo with enzalutamide
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 3, 2019)
Original Estimated Enrollment  ICMJE
 (submitted: January 3, 2018)
Estimated Study Completion Date  ICMJE November 25, 2024
Estimated Primary Completion Date August 22, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Histologically or cytologically confirmed adenocarcinoma of the prostate withoutsmall cell or signet cell features

Asymptomatic or mildly symptomatic metastatic castration resistant prostate cancer (mCRPC) (score on BPI-SF Question #3 must be < 4).

For enrollment into Part 2 only (optional in Part 1): assessment of DDR mutation status

Consent to a saliva sample collection for a germline comparator unless prohibited by local regulations or ethics committee decision (optional for patients in Part 1).

Surgically or medically castrated, with serum testosterone ? 50 ng/dL (? 1.73 nmol/L) at screening.

Metastatic disease in bone documented on bone scan or in soft tissue documented on CT/MRI scan.

Progressive disease at study entry in the setting of medical or surgical castration as defined by 1 or more of the following 3 criteria:

  • Prostate specific antigen (PSA) progression defined by a minimum of 2 rising PSA values from 3 consecutive assessments with an interval of at least 7 days between assessments..
  • Soft tissue disease progression as defined by RECIST 1.1.
  • Bone disease progression defined by Prostate Cancer Working Group 3 (PCWG3) with 2 or more new metastatic bone lesions on a whole body radionuclide bone scan.

Ongoing bisphosphonate or denosumab use prior to Day 1 (Part 1) or randomization (Part 2) is allowed but not mandatory.

Eastern Cooperative Oncology Group (ECOG) performance status ? 1.

Life expectancy ? 12 months as assessed by the investigator.

Able to swallow the study drug and have no known intolerance to study drugs or excipients.

Must agree to use a condom when having sex with a partner from the time of the first dose of study drug through 4 months after last dose of study treatment. Must also agree for female partner of childbearing potential to use an additional highly effective form of contraception from the time of the first dose of study treatment through 4 months after last dose of study treatment when having sex with a non pregnant female partner of childbearing potential.

Must agree not to donate sperm from the first dose of study drug to 4 months after the last dose of study drug.

Evidence of a personally signed and dated informed consent document (and molecular prescreening consent if appropriate) indicating that the patient [or a legally acceptable representative/legal guardian] has been informed of all pertinent aspects of the study.

Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

Any prior systemic cancer treatment initiated in in the non metastatic CRPC and mCRPC disease state.

Patients whose only evidence of metastasis is adenopathy below the aortic bifurcation.

Prior treatment with second-generation androgen receptor inhibitors (enzalutamide, apalutamide, and darolutamide), a PARP inhibitor, cyclophosphamide, or mitoxantrone for prostate cancer.

Prior treatment with platinum-based chemotherapy within 6 months (from the last dose) prior to Day 1 (Part 1) or randomization (Part 2), or any history of disease progression on platinum-based therapy within 6 months (from the last dose).

Treatment with cytotoxic chemotherapy, biologic therapy including sipuleucel T, or radionuclide therapy received in the castration-sensitive prostate cancer is NOT exclusionary if discontinued in the 28 days prior to Day 1 (Part 1) or randomization (Part 2).

Treatment with any investigational agent within 4 weeks before Day 1 (Part 1) or randomization (Part 2).

Prior treatment with opioids for pain related to either primary prostate cancer or metastasis within 28 days prior to Day 1 (Part 1) or randomization (Part 2).

Current use of potent P-gp inhibitors within 7 days prior to Day 1 (Part 1) or randomization (Part 2).

Major surgery (as defined by the investigator) within 2 weeks before Day 1 (Part 1) or randomization (Part 2), or palliative localized radiation therapy within 3 weeks before randomization (Part 2).

Clinically significant cardiovascular disease

Significant renal dysfunction as defined by any of the following laboratory abnormalities:

? Renal: eGFR < 30 mL/min/1.73 m2 by the MDRD equation (available via

Patients enrolled in Part 1 only: Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2) at screening.

Significant hepatic dysfunction as defined by any of the following laboratory abnormalities on screening labs:

  • Total serum bilirubin >1.5 times the upper limit of normal (ULN) (>3 × ULN for patients with documented Gilbert syndrome or for whom indirect bilirubin concentrations suggest an extrahepatic source of elevation).
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times ULN (>5 × ULN if liver function abnormalities are due to hepatic metastasis).
  • Albumin <2.8 g/dL

Absolute neutrophil count < 1500/µL, platelets < 100,000/µL, or hemoglobin < 9 g/dL (may not have received growth factors or blood transfusions within 14 days before obtaining the hematology values at screening).

Known or suspected brain metastasis or active leptomeningeal disease.

Symptomatic or impending spinal cord compression or cauda equina syndrome.

Any history of myelodysplastic syndrome, acute myeloid leukemia, or prior malignancy except any of the following:

  • Carcinoma in situ or non melanoma skin cancer
  • Any prior malignancies ?3 years before randomization with no subsequent evidence of recurrence or progression regardless of the stage.
  • Stage 0 or Stage 1 cancer <3 years before randomization that has a remote probability of recurrence or progression in the opinion of the investigator

Gastrointestinal disorder affecting absorption.

Fertile male subjects who are unwilling or unable to use highly effective methods of contraception for the duration of the study and for 4 months after the last dose of investigational product.

Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.

Other acute or chronic medical (concurrent disease, infection, or comorbidity) or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that interferes with ability to participate in the study, may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke, significant brain trauma). Also, history of loss of consciousness or transient ischemic attack within 12 months of randomization (Part 2).

Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Gender Based Eligibility:Yes
Gender Eligibility Description:Men at least 18 years of age. For Japan, at least 20 years of age.
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Argentina,   Australia,   Belgium,   Brazil,   Canada,   Chile,   China,   Czechia,   Finland,   France,   Germany,   Hungary,   Israel,   Italy,   Japan,   Korea, Republic of,   New Zealand,   Norway,   Peru,   Poland,   Portugal,   South Africa,   Spain,   Sweden,   United Kingdom,   United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT03395197
Other Study ID Numbers  ICMJE C3441021
2017-003295-31 ( EudraCT Number )
TALAPRO-2 ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at:….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Astellas Pharma Inc
Investigators  ICMJE
Study Director:Pfizer Call CenterPfizer
PRS Account Pfizer
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP